Anethole Trithione (AT)

[Edit]

Anethole trithione; anetholtrithione; anetholtrithion

Anethole Trithione (AT)
Anethole trithione, anetholtrithione, or anetholtrithion (JAN) is a drug used in the treatment of dry mouth. It is listed in the U.S. National Cancer Institute's Dictionary of Cancer Terms as being studied in the treatment of cancer.
Saliva protects the oral mucosa, inhibiting microbial overgrowth. Hyposalivation, therefore, induces multiple oral disorders, although treatment of hyposalivation is very difficult. A cholagogue, anethole trithione (AT) was administered to patients with symptomatic hyposalivation (xerostomia) caused by senile hypofunction (4 men and 17 women; senile group), medications (6 men and 17 women; drug group), and oral cancer therapy (two men and three women; cancer group). AT sufficiently stimulates salivation and improves xerostomia.

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Complete Antigen of Anethole Trithione (AT) Antigenic Transformation Customized Service Offer
Antibodies n/a Monoclonal Antibody to Anethole Trithione (AT) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Anethole Trithione (AT) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Anethole Trithione (AT) CLIA Kit Customized Service Offer
n/a ELISA Kit for Anethole Trithione (AT) ELISA Kit Customized Service Offer